Protocol and rationale for a randomised, double-blind, placebo-controlled phase 3 trial of admilparant (BMS-986278), an oral lysophosphatidic acid receptor 1 antagonist, in patients with idiopathic pulmonary fibrosis: ALOFT-IPF.

IF 4 3区医学 Q1 RESPIRATORY SYSTEM

BMJ Open Respiratory Research Pub Date : 2026-10-09 DOI:10.1136/bmjresp-2026-004324

Toby M Maher, Fernando Martinez, Michael Kreuter, Tamera J Corte, Marlies Wijsenbeek, Takashi Ogura, Takafumi Suda, Zuojun Xu, Aryeh Fischer, Yue Wang, Elizabeth Cerullo, Walid Elsharkawi, Aditya Patel, Vincent Cottin

引用次数: 0

查看原文本刊更多论文

口服溶血磷脂酸受体1拮抗剂admilparant （BMS-986278）用于特发性肺纤维化患者的随机、双盲、安慰剂对照3期试验的方案和基本原理：ALOFT-IPF。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMJ Open Respiratory Research RESPIRATORY SYSTEM-

CiteScore

6.60

自引率

2.40%

发文量

审稿时长

12 weeks

期刊介绍： BMJ Open Respiratory Research is a peer-reviewed, open access journal publishing respiratory and critical care medicine. It is the sister journal to Thorax and co-owned by the British Thoracic Society and BMJ. The journal focuses on robustness of methodology and scientific rigour with less emphasis on novelty or perceived impact. BMJ Open Respiratory Research operates a rapid review process, with continuous publication online, ensuring timely, up-to-date research is available worldwide. The journal publishes review articles and all research study types: Basic science including laboratory based experiments and animal models, Pilot studies or proof of concept, Observational studies, Study protocols, Registries, Clinical trials from phase I to multicentre randomised clinical trials, Systematic reviews and meta-analyses.